产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
| 名称 | KMS-11 (人多发性骨髓瘤克隆细胞) (STR鉴定正确) |
| 种属 | 人 |
| 生长特性 | 半贴半悬 |
| 细胞形态 | 淋巴细胞样 |
| 冻存条件 | 冻存液：55% 基础培养基+40%FBS+5%DMSO 温度：液氮 |
| 培养方案A（默认） |
培养条件:
气相：空气，95%；CO2，5%, 温度：37℃
|
| 推荐传代比例 | 3×10^5-5×10^5 cells/ml |
| 推荐换液频率 | 2-3天/次 |
| 背景描述 | 该细胞源自一名67岁患有骨髓瘤的女性的胸腔积液。 |
| 年龄（性别） | 女性；67岁 |
| 细胞类型 | 肿瘤细胞 |
| 肿瘤类型 | 骨髓瘤细胞 |
| 生物安全等级 | BSL-1 |
| 倍增时间 | 36 hours (PubMed=2519219); 70 hours (PubMed=25984343) |
| 保藏机构 | JCRB; JCRB1179 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 13 D2S1338 18,21 D3S1358 15 D5S818 10,12 D7S820 11,12 D8S1179 13 D13S317 12 D16S539 9,13 D18S51 13,14 D19S433 12.2,13.2,14 D21S11 28,30 FGA 22,24 PentaD 11,12 PentaE 15,16 TH01 6,9 TPOX 12 vWA 17,18 D6S1043 12,13 D12S391 21,23 D2S441 11,12 -
STR鉴定图
-
参考文献
-
Identification of Piperazinyl–Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation (2024-01-31)
作者：Wei Ding:1.Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P. R. China. ; Liting Yan:1.College of Life Sciences, Shaanxi Normal University, Xi'an 710119, P. R. China. ; Li Sheng:1.Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P. R. China. ; Shuting Chen:1.College of Life Sciences, Shaanxi Normal University, Xi'an 710119, P. R. China. ; Ying Li:1.College of Life Sciences, Shaanxi Normal University, Xi'an 710119, P. R. China. ; Shihao Cheng:1.Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, P. R. China. ; Lijun Luo:1.Beijing Key Laboratory of
期刊：Identification of Piperazinyl–Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation
DOI：10.1021/acs.jmedchem.3c02040
影响因子 ：7.3
引用产品： KMS-11 细胞 , MDA-MB-453 细胞
FAQs
Q：{{item.question}}
A：
产品资料
识别码示意图
